Sundance Clinical Research, LLC
Welcome,         Profile    Billing    Logout  
 4 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wadsworth, Larkin
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
NCT06269705: ZILRETTA in Subjects With Shoulder Osteoarthritis

Recruiting
3
250
US
ZILRETTA, TCA-IR, Placebo, Normal Saline
Pacira Pharmaceuticals, Inc
Glenohumeral Osteoarthritis
08/25
08/25
NCT05722522: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
34
Europe, Canada, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24
NCT06680375: A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Recruiting
2
780
US
Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo, Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA, Phase 2 selected SARS-CoV-2 mRNA
GlaxoSmithKline
COVID-19
04/25
09/25
NCT05477186: Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Completed
1
180
US, RoW
CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (75 μg), CV0501 (100 μg), CV0501 (150 μg), CV0501 (200 μg)
GlaxoSmithKline
COVID-19, SARS-CoV-2
08/23
08/23
Weinstock, Leonard B
NCT05652907: Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

Terminated
2
2
Canada, US
FSD201, Placebo
FSD Pharma, Inc.
Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
05/23
05/23
NCT04781387: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

Active, not recruiting
2
108
Canada, US
CRS3123, Active Comparator
Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection
02/24
04/24
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25

Download Options